Sabra Health Care REIT overview and recent performance snapshot

Sabra Health Care REIT (SBRA) has drawn investor attention recently as a healthcare focused real estate investment trust with a market cap of about US$5.2b and a last closing price of US$20.72.

The company reports revenue of US$815.7m and net income of US$156.2m from investments in healthcare properties across the United States and Canada, with both revenue and net income showing annual growth based on the latest available figures.

For shareholders watching recent returns, the stock is roughly flat over the past week, modestly higher over the past month, and slightly higher over the past 3 months, with a stronger gain on a year to date and 1 year total return basis.

Recent trading shows a modest 3.1% 1 month share price return, while the 1 year total shareholder return of 25.2% and very large 3 year total shareholder return suggest momentum has been building over a longer horizon.

If Sabra’s performance has you thinking about where else capital might work hard, this could be a good moment to scan 35 power grid technology and infrastructure stocks

So with solid recent total returns, a value score of 4 and an estimated intrinsic value suggesting a sizeable discount, is Sabra Health Care REIT still mispriced, or is the market already baking in future growth?

Most Popular Narrative: 5.8% Undervalued

At a last close of $20.72 against a narrative fair value of $22.00, Sabra Health Care REIT is framed as modestly undervalued, with the story hinging on how its senior housing exposure converts into cash flow over time.

Persistent and accelerating demand for senior housing, assisted living, and memory care driven by the aging U.S. population, specifically the Baby Boomer cohort, continues to outpace new supply due to high barriers to development. This supports higher occupancy, rising rents, and long-term revenue and cash NOI growth across Sabra's property portfolio.

Curious what kind of revenue growth, margin shape, and future earnings multiple sit behind that fair value tag, the narrative leans on several moving pieces. The real interest is how growth, profitability, and valuation are stitched together into one long term cash flow story.

Result: Fair Value of $22.00 (UNDERVALUED)

However, you still need to weigh execution risk around new operators and senior housing acquisitions, along with possible pressure from future Medicare or Medicaid reimbursement changes.

Next Steps

If this mix of optimism and concern feels finely balanced, do not sit on the sidelines. Review the numbers yourself and weigh Sabra's potential against its challenges with 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

Do not stop your research with a single stock. Broader ideas can help you spot opportunities, pressure test your thinking, and stay ready when markets shift.

• Target reliable income by reviewing companies with higher yields and resilient payouts through the 10 dividend fortresses.
• Hunt for potential bargains by scanning financially healthy stocks that trade below their estimated worth using the 48 high quality undervalued stocks.
• Focus on resilience by checking companies with stronger balance sheets and fundamentals via the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.